In a highly-anticipated comeback to Healthcare Unfiltered, Dave Feldman, the seasoned senior software engineer and entrepreneurial mind, delves into uncharted territories of the keto diet, cholesterol dynamics, and lipids, unveiling a riveting discourse intricately intertwined with a novel cardiac study.
Feldman unfolds the layers of his personal journey with the keto diet, evolving into a recognized authority on lipids. He showcases the intriguing sequence of events that propelled him to design a study involving cardiac tests and a cohort of 100 patients committed to a low-carb, keto lifestyle for over a year. Could this study revolutionize the way cardiologists and primary care providers approach cholesterol management? Will it unveil evidence challenging the conventional prescription of statins to lower LDL?
You should watch prior appearances for Dave on my show leading to this one. As always, don’t forget to hit the subscribe and like buttons, and share with friends and colleagues who might be interested in this topic.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
